Medicare AdvantagePrior AuthMedium impact
Tirosint SOL (levothyroxine sodium solution) (New)
Humana·Endocrinology, Family Medicine, Internal Medicine +2 more·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage now requires prior authorization for Tirosint SOL (levothyroxine sodium solution) effective January 1, 2026. This is a new policy covering a liquid form of thyroid hormone replacement therapy with specific approval criteria for hypothyroidism and thyroid cancer management.
Action Required
By January 1, 2026: Billing team must update prior authorization tracking system to include Tirosint SOL (levothyroxine sodium solution) for Humana Medicare Advantage patients. Providers must obtain prior auth before prescribing by documenting that patient meets criteria for hypothyroidism replacement therapy or thyroid cancer management, and confirming no exclusions apply (benign thyroid nodules or subacute thyroiditis). Update EMR alerts for thyroid medication prescribing. Failure to obtain prior auth will result in prescription denials.